Title

Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain
A Phase III, Multicenter, Randomized Study to Assess the Efficacy and Safety of 0,5 mg Tizaspray® Administered Intranasally Versus Sirdalud® 2 mg Tablets, in Patients With Acute Low Back Pain
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    tizanidine ...
  • Study Participants

    117
Open label, randomized, controlled, multicenter study with two parallel groups of patients
This is a phase III, open label, randomized, controlled, multicenter study with two parallel groups of patients.

Tizaspray® 0.5 mg (a new pharmaceutical form, liquid nasal spray solution), is proposed in this trial as a ready to use treatment for short term therapy of painful muscle spasms as the acute low back pain.
Study Started
Oct 31
2016
Primary Completion
Jan 31
2017
Study Completion
Feb 28
2017
Last Update
Jan 16
2018

Device Tizaspray® administered intranasally

0,5 mg Tizaspray® administered intranasally

  • Other names: Tizaspray®

Drug Sirdalud® 2 mg tablets administered

Sirdalud® 2 mg tablets administered in patients with acute low back pain

  • Other names: Sirdalud®

Tizaspray® Experimental

Tizaspray® administered intranasally in patients with acute low back pain

Sirdalud® Active Comparator

Sirdalud® 2 mg tablets administered in patients with acute low back pain

Criteria

Inclusion Criteria:

Age between 18 and 65 years old
Average low back pain intensity moderate to severe (≥ 60 mm in the VAS) at Visit 1
Positivity to Schober test (i.e. measure < 5 cm) at Visit 1
Acute low back pain started at least 24 hours prior to inclusion in the trial and more than 6 weeks after the last episode of acute low back pain
Negative pregnancy test for women of childbearing potential (to be performed at Visit 1) and use of an acceptable mean of contraception (condom or mechanical methods) in the previous 2 months and for whole duration of the study
Signed Informed Consent

Exclusion Criteria:

History of chronic low back pain
Current treatment with drugs having significant effects at the alpha2 receptors whether agonist (i.e., clonidine, methyldopa) or antagonist (i.e., phenothiazines, imipramine)
Current treatment with any other muscle relaxant or any drugs having muscle relaxant properties
Known allergies, hypersensitivity, or intolerance to tizanidine or paracetamol or any excipients used in their manufacture (included patients with known rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption)
Signs of nasal congestion, nasal polyps, mucosal lesions of the nostrils, postnasal drip of any etiology or any clinically significant nasal pathology that may affect the absorption of study medication or the assessment of safety
Evidence of clinically unstable disease, as determined by medical history, physical examination, that, in the Investigator's opinion, preclude entry into the study
Spinal surgery within 1 year of study entry
Evidence of clinical gastrointestinal malabsorption
Use of steroids within 3 months of study entry or any other long-term treatment with steroids
Use of NSAID's or other anti-inflammatory drugs 6 hours prior to study inclusion
Use of fluvoxamine or ciprofloxacin, or other inhibitors of CYP1A2 such as antiarrhythmics (amiodarone, mexiletine, propafenone), cimetidine, fluoroquinolones (enoxacin, pefloxacin, norfloxacin), rofecoxib, oral contraceptives, and ticlopidine
Use of hypnotics or other CNS depressants
Blood pressure <100/70 mmHg
History of lumbar spinal stenosis, fibromyalgia, or ankylosing spondylitis
Severe scoliosis
More severe pain in a region other than the lower back
Acute low back pain associated with chills or fever
Pregnancy, breast feeding
Treatment with another investigational agent within the last 30 days
Known or suspected history of alcohol or drug abuse based on medical history, physical examination, or the Investigator's clinical judgment
No Results Posted